|Bid||7.11 x 29200|
|Ask||7.12 x 27000|
|Day's range||6.94 - 7.27|
|52-week range||6.44 - 20.15|
|Beta (5Y monthly)||2.89|
|PE ratio (TTM)||N/A|
|Earnings date||15 Feb 2023 - 20 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.43|
In this video, I talk about Palantir (NYSE: PLTR), which is down 60% year to date, and why that might be an excellent opportunity for long-term investors. For the full insights, do watch the video, consider subscribing, and click the special offer link below.
The Centers for Disease Control and Prevention (CDC) has renewed a software agreement with Palantir Technologies (NYSE: PLTR), awarding the tech company a new five-year, $443 million contract. Investors are applauding the deal, sending shares of Palantir up as much as 5% on Wednesday. Palantir provides data analytics tools for government and commercial customers.
A soft earnings report and bankruptcy at one of its investees was enough to sink this software favorite.